179 related articles for article (PubMed ID: 36285481)
61. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
62. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor.
Abhyankar S; DeJarnette S; Aljitawi O; Ganguly S; Merkel D; McGuirk J
Bone Marrow Transplant; 2012 Apr; 47(4):483-7. PubMed ID: 21725372
[TBL] [Abstract][Full Text] [Related]
63. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation.
Hauge AW; Haastrup EK; Sengeløv H; Minulescu L; Dickmeiss E; Fischer-Nielsen A
Transfusion; 2014 Apr; 54(4):1055-8. PubMed ID: 23944772
[TBL] [Abstract][Full Text] [Related]
64. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
[TBL] [Abstract][Full Text] [Related]
65. Characteristics of cells with engraftment capacity within CD34+ cell population upon G-CSF and Plerixafor mobilization.
Mombled M; Rodriguez L; Avalon M; Duchez P; Vlaski-Lafarge M; Debeissat C; Pérard B; Sawai KM; Pasquet JM; Bijou F; Thévenot F; Cabantous T; Ivanovic Z; Brunet de la Grange P
Leukemia; 2020 Dec; 34(12):3370-3381. PubMed ID: 32690879
[TBL] [Abstract][Full Text] [Related]
66. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
67. [Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization].
Duan WB; Dou XL; Lei L; Wang FR; Huang XJ; Lu J
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):21-26. PubMed ID: 33677864
[No Abstract] [Full Text] [Related]
68. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C
Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720
[TBL] [Abstract][Full Text] [Related]
69. Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era.
Arora S; Majhail NS; Liu H
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):200-205. PubMed ID: 30679106
[TBL] [Abstract][Full Text] [Related]
70. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation.
Sanikommu SR; Reese ES; He J; Lee C; Ai J; Butler CM; Jacobs R; Hu B; Atrash S; Trivedi J; Bhutani M; Voorhees P; Usmani SZ; Ghosh N; Fasan O; Druhan LJ; Symanowski J; Copelan EA; Avalos BR
J Clin Apher; 2021 Aug; 36(4):553-562. PubMed ID: 33710672
[TBL] [Abstract][Full Text] [Related]
71. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
[TBL] [Abstract][Full Text] [Related]
72. Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.
Shi PA; Miller LK; Isola LM
Transfusion; 2014 May; 54(5):1263-8. PubMed ID: 24128272
[TBL] [Abstract][Full Text] [Related]
73. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.
Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A
Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941
[TBL] [Abstract][Full Text] [Related]
74. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
Bakeer M; Zubair AC; Roy V
Cytotherapy; 2020 Jan; 22(1):16-20. PubMed ID: 31879152
[TBL] [Abstract][Full Text] [Related]
75. Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor.
Avramova BE; Yordanova MN; Konstantinov DN; Bobev DG
Drug Des Devel Ther; 2011; 5():407-9. PubMed ID: 21966213
[TBL] [Abstract][Full Text] [Related]
76. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
Zhu J; Huang H; Chen H; Zhang X; Li Z; Wu D; Zhou D; Song Y; Hu Y; Liang Y; Ren H; Huang H; Li N; Chen H; Hu J; Li J; Meng R; Wu J; Yu D; Huang X
Transfusion; 2018 Jan; 58(1):81-87. PubMed ID: 29238988
[TBL] [Abstract][Full Text] [Related]
77. Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.
Shastri A; Budhathoki A; Barta SK; Kornblum N; Derman O; Battini R; Raghupathy R; Verma AK; Frenette PS; Braunschweig I; Janakiram M
Am J Hematol; 2017 Oct; 92(10):1047-1051. PubMed ID: 28675459
[TBL] [Abstract][Full Text] [Related]
78. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
Biol Blood Marrow Transplant; 2019 Jan; 25(1):34-40. PubMed ID: 30149148
[TBL] [Abstract][Full Text] [Related]
79. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
[TBL] [Abstract][Full Text] [Related]
80. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]